Format
Sort by
Items per page

Send to

Choose Destination

Best matches for González-Suárez E[au]:

Search results

Items: 1 to 50 of 52

1.

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.

Piqué L, Martinez de Paz A, Piñeyro D, Martínez-Cardús A, Castro de Moura M, Llinàs-Arias P, Setien F, Gomez-Miragaya J, Gonzalez-Suarez E, Sigurdsson S, Jonasson JG, Villanueva A, Vidal A, Davalos V, Esteller M.

Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0936-x. [Epub ahead of print]

PMID:
31409895
2.

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E.

Mol Cancer Res. 2019 Oct;17(10):2063-2076. doi: 10.1158/1541-7786.MCR-19-0040. Epub 2019 Jul 18.

PMID:
31320385
3.

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.

Cancer Res. 2019 Aug 15;79(16):4258-4270. doi: 10.1158/0008-5472.CAN-18-3835. Epub 2019 Jun 18.

PMID:
31213465
4.

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ.

Cancer Treat Rev. 2019 Jun;76:57-67. doi: 10.1016/j.ctrv.2019.05.003. Epub 2019 May 15. Review.

5.

PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma.

Bernat-Peguera A, Simón-Extremera P, da Silva-Diz V, López de Munain M, Díaz-Gil L, Penin RM, González-Suárez E, Pérez Sidelnikova D, Bermejo O, Viñals JM, Viñals F, Muñoz P.

Oncogene. 2019 Jun;38(25):5021-5037. doi: 10.1038/s41388-019-0773-y. Epub 2019 Mar 15.

6.

Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.

Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA.

PLoS One. 2018 Nov 12;13(11):e0207586. doi: 10.1371/journal.pone.0207586. eCollection 2018.

7.

European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers.

Koledova Z, Howard BA, Englund J, Bach K, Bentires-Alj M, Gonzalez-Suarez E.

Breast Cancer Res. 2018 Sep 4;20(1):102. doi: 10.1186/s13058-018-1032-9.

8.

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Pérez-Montoyo H, Serra V, González-Suárez E, Stracker TH, Nebreda AR.

Cancer Cell. 2018 Jun 11;33(6):1094-1110.e8. doi: 10.1016/j.ccell.2018.04.010. Epub 2018 May 24.

9.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
10.

Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.

Pérez-Salvia M, Simó-Riudalbas L, Llinàs-Arias P, Roa L, Setien F, Soler M, de Moura MC, Bradner JE, Gonzalez-Suarez E, Moutinho C, Esteller M.

Oncotarget. 2017 May 29;8(31):51621-51629. doi: 10.18632/oncotarget.18255. eCollection 2017 Aug 1.

11.

Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.

Gomez-Miragaya J, González-Suárez E.

Mol Cell Oncol. 2017 Jun 28;4(4):e1338208. doi: 10.1080/23723556.2017.1338208. eCollection 2017.

12.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E.

Stem Cell Reports. 2017 May 9;8(5):1392-1407. doi: 10.1016/j.stemcr.2017.03.026. Epub 2017 Apr 27.

13.

RANKL inhibitors for osteosarcoma treatment: hope and caution.

Trinidad EM, González-Suárez E.

Ann Transl Med. 2016 Dec;4(24):534. doi: 10.21037/atm.2016.12.10. No abstract available.

14.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

15.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

16.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA.

Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427. Epub 2016 Dec 19.

17.

Cancer network activity associated with therapeutic response and synergism.

Serra-Musach J, Mateo F, Capdevila-Busquets E, de Garibay GR, Zhang X, Guha R, Thomas CJ, Grueso J, Villanueva A, Jaeger S, Heyn H, Vizoso M, Pérez H, Cordero A, Gonzalez-Suarez E, Esteller M, Moreno-Bueno G, Tjärnberg A, Lázaro C, Serra V, Arribas J, Benson M, Gustafsson M, Ferrer M, Aloy P, Pujana MÀ.

Genome Med. 2016 Aug 24;8(1):88. doi: 10.1186/s13073-016-0340-x.

18.

RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

Yoldi G, Pellegrini P, Trinidad EM, Cordero A, Gomez-Miragaya J, Serra-Musach J, Dougall WC, Muñoz P, Pujana MA, Planelles L, González-Suárez E.

Cancer Res. 2016 Oct 1;76(19):5857-5869. Epub 2016 Aug 1.

19.

RANKL/RANK control Brca1 mutation- .

Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.

Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

20.

RANK as a therapeutic target in cancer.

González-Suárez E, Sanz-Moreno A.

FEBS J. 2016 Jun;283(11):2018-33. doi: 10.1111/febs.13645. Epub 2016 Jan 28. Review.

21.

Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression.

da Silva-Diz V, Simón-Extremera P, Bernat-Peguera A, de Sostoa J, Urpí M, Penín RM, Sidelnikova DP, Bermejo O, Viñals JM, Rodolosse A, González-Suárez E, Moruno AG, Pujana MÁ, Esteller M, Villanueva A, Viñals F, Muñoz P.

Cancer Res. 2016 Mar 1;76(5):1245-59. doi: 10.1158/0008-5472.CAN-15-1631. Epub 2015 Dec 30.

22.

Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation.

Cordero A, Pellegrini P, Sanz-Moreno A, Trinidad EM, Serra-Musach J, Deshpande C, Dougall WC, Pujana MA, González-Suárez E.

Stem Cells. 2016 Apr;34(4):1027-39. doi: 10.1002/stem.2271. Epub 2016 Jan 13.

23.

FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.

Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A.

Oncotarget. 2015 Dec 29;6(42):44254-73. doi: 10.18632/oncotarget.5471.

24.

Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.

Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA.

PLoS One. 2015 Jul 13;10(7):e0132546. doi: 10.1371/journal.pone.0132546. eCollection 2015. Erratum in: PLoS One. 2018 Nov 12;13(11):e0207586.

25.

Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.

Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T.

PLoS One. 2015 Jun 24;10(6):e0131241. doi: 10.1371/journal.pone.0131241. eCollection 2015.

26.

APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer.

García-Castro A, Zonca M, Florindo-Pinheiro D, Carvalho-Pinto CE, Cordero A, Gutiérrez del Fernando B, García-Grande A, Mañes S, Hahne M, González-Suárez E, Planelles L.

Carcinogenesis. 2015 May;36(5):574-84. doi: 10.1093/carcin/bgv020. Epub 2015 Mar 6.

PMID:
25750171
27.

A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition.

Carmona FJ, Davalos V, Vidal E, Gomez A, Heyn H, Hashimoto Y, Vizoso M, Martinez-Cardus A, Sayols S, Ferreira HJ, Sánchez-Mut JV, Morán S, Margelí M, Castella E, Berdasco M, Stefansson OA, Eyfjord JE, Gonzalez-Suarez E, Dopazo J, Orozco M, Gut IG, Esteller M.

Cancer Res. 2014 Oct 1;74(19):5608-19. doi: 10.1158/0008-5472.CAN-13-3659. Epub 2014 Aug 8.

28.

Targeting RANKL in metastasis.

Dougall WC, Holen I, González Suárez E.

Bonekey Rep. 2014 Apr 9;3:519. doi: 10.1038/bonekey.2014.14. eCollection 2014. Review.

29.

Linkage of DNA methylation quantitative trait loci to human cancer risk.

Heyn H, Sayols S, Moutinho C, Vidal E, Sanchez-Mut JV, Stefansson OA, Nadal E, Moran S, Eyfjord JE, Gonzalez-Suarez E, Pujana MA, Esteller M.

Cell Rep. 2014 Apr 24;7(2):331-338. doi: 10.1016/j.celrep.2014.03.016. Epub 2014 Apr 3.

30.

Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial.

Ng K, Scott JB, Drake BF, Chan AT, Hollis BW, Chandler PD, Bennett GG, Giovannucci EL, Gonzalez-Suarez E, Meyerhardt JA, Emmons KM, Fuchs CS.

Am J Clin Nutr. 2014 Mar;99(3):587-98. doi: 10.3945/ajcn.113.067777. Epub 2013 Dec 24.

31.

Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis.

Pellegrini P, Cordero A, Gallego MI, Dougall WC, Muñoz P, Pujana MA, Gonzalez-Suarez E.

Stem Cells. 2013 Sep;31(9):1954-65. doi: 10.1002/stem.1454. Erratum in: Stem Cells. 2014 Apr;32(4):1057. Purificación, Muñoz [corrected to Muñoz, Purificación]. Stem Cells. 2014 Feb;32(2):600. Pasquale, Pellegrini [corrected to Pellegrini, Pasquale]; Alex, Cordero [corrected to Cordero, Alex]; Marta Ines, Gallego [corrected to Gallego, Marta Ines ]; William, Dougall C [corrected to Dougall, William C]; Miguel Angel, Pujana [corrected to Pujana,.

32.

Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.

Muñoz-Pinedo C, González-Suárez E, Portela A, Gentilella A, Esteller M.

Cancer Res. 2013 Jul 15;73(14):4185-9. doi: 10.1158/0008-5472.CAN-13-0512. Epub 2013 May 17.

33.

Parental perceptions of a motivational interviewing-based pediatric obesity prevention intervention.

Woo Baidal JA, Price SN, Gonzalez-Suarez E, Gillman MW, Mitchell K, Rifas-Shiman SL, Horan CM, Gortmaker SL, Taveras EM.

Clin Pediatr (Phila). 2013 Jun;52(6):540-8. doi: 10.1177/0009922813483170. Epub 2013 Apr 5.

34.

Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis.

da Silva-Diz V, Solé-Sánchez S, Valdés-Gutiérrez A, Urpí M, Riba-Artés D, Penin RM, Pascual G, González-Suárez E, Casanovas O, Viñals F, Paramio JM, Batlle E, Muñoz P.

Oncogene. 2013 Aug 8;32(32):3732-43. doi: 10.1038/onc.2012.375. Epub 2012 Sep 3.

PMID:
22945646
35.

Dimensions of religiousness and cancer screening behaviors among church-going Latinas.

Allen JD, Pérez JE, Pischke CR, Tom LS, Juarez A, Ospino H, Gonzalez-Suarez E.

J Relig Health. 2014 Feb;53(1):190-203. doi: 10.1007/s10943-012-9606-9.

36.

Identification of NOG as a specific breast cancer bone metastasis-supporting gene.

Tarragona M, Pavlovic M, Arnal-Estapé A, Urosevic J, Morales M, Guiu M, Planet E, González-Suárez E, Gomis RR.

J Biol Chem. 2012 Jun 15;287(25):21346-55. doi: 10.1074/jbc.M112.355834. Epub 2012 Apr 30.

37.

RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Muñoz P, Viñals F, Tometsko M, Branstetter D, Dougall WC, González-Suárez E.

Cancer Res. 2012 Jun 1;72(11):2879-88. doi: 10.1158/0008-5472.CAN-12-0044. Epub 2012 Apr 10.

38.

Evidence for a link between TNFRSF11A and risk of breast cancer.

Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Mariette F, Bernard L, Radice P, Kaufman B, Laitman Y, Milgrom R, Friedman E, Sáez ME, Climent F, Soler MT, Diez O, Balmaña J, Lasa A, Ramón y Cajal T, Miramar MD, de la Hoya M, Pérez-Segura P, Caldés T, Moreno V, Urruticoechea A, Brunet J, Lázaro C, Blanco I, Pujana MA, González-Suárez E.

Breast Cancer Res Treat. 2011 Oct;129(3):947-54. doi: 10.1007/s10549-011-1546-7. Epub 2011 May 4.

PMID:
21541702
39.

RANKL inhibition: a promising novel strategy for breast cancer treatment.

González-Suárez E.

Clin Transl Oncol. 2011 Apr;13(4):222-8. doi: 10.1007/s12094-011-0646-5. Review.

PMID:
21493182
40.

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC.

Nature. 2010 Nov 4;468(7320):103-7. doi: 10.1038/nature09495. Epub 2010 Sep 29.

PMID:
20881963
41.

BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.

Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M.

J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6. doi: 10.1200/JCO.2010.30.1010. Epub 2010 Aug 2. No abstract available.

PMID:
20679605
42.

BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.

Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL.

J Immunol. 2007 Feb 1;178(3):1523-33.

44.

Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-beta signaling.

Geserick C, Tejera A, González-Suárez E, Klatt P, Blasco MA.

Oncogene. 2006 Jul 20;25(31):4310-9. Epub 2006 Feb 27.

PMID:
16501597
45.

Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice.

González-Suárez E, Geserick C, Flores JM, Blasco MA.

Oncogene. 2005 Mar 24;24(13):2256-70.

PMID:
15688016
46.

Implementation of a cancer prevention program for working class, multiethnic populations.

Lobb R, Gonzalez Suarez E, Fay ME, Gutheil CM, Hunt MK, Fletcher RH, Emmons KM.

Prev Med. 2004 Jun;38(6):766-76.

PMID:
15193897
47.

Telomere dysfunction results in enhanced organismal sensitivity to the alkylating agent N-methyl-N-nitrosourea.

González-Suárez E, Goytisolo FA, Flores JM, Blasco MA.

Cancer Res. 2003 Nov 1;63(21):7047-50.

48.

Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development.

González-Suárez E, Flores JM, Blasco MA.

Mol Cell Biol. 2002 Oct;22(20):7291-301.

50.

Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability.

Samper E, Goytisolo FA, Ménissier-de Murcia J, González-Suárez E, Cigudosa JC, de Murcia G, Blasco MA.

J Cell Biol. 2001 Jul 9;154(1):49-60.

Supplemental Content

Loading ...
Support Center